p38 MAP kinase inhibitors (AbbVie)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namep38 MAP kinase inhibitors (AbbVie)
Drug Alias Namep38 MAP kinase inhibitors (Abbott)p38 MAPK inhibitors (Abbott)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 α mitogen-activated protein kinase inhibitors
TargetsP38 α mitogen-activated protein kinase
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAbbott Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott LaboratoriesAbbvie Inc
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A